spotlight on biosimilars

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Sophia Humphreys, PharmD, MHA, BCBBS

Not only can biosimilars impact the health of our patients with cancer, but they can also contribute to cost savings for the healthcare system as a whole. Here to dive further into the economic impacts of biosimilars in the oncology space with Dr. Mary Katherine Cheeley is Dr. Sophia Humphreys, Director of System Pharmacy Formulary Management and Clinical Programs at Sutter Health.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Sophia Humphreys, PharmD, MHA, BCBBS

Not only can biosimilars impact the health of our patients with cancer, but they can also contribute to cost savings for the healthcare system as a whole. Here to dive further into the economic impacts of biosimilars in the oncology space with Dr. Mary Katherine Cheeley is Dr. Sophia Humphreys, Director of System Pharmacy Formulary Management and Clinical Programs at Sutter Health.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Arghavan Almony, MD

The production of biosimilar therapies is setting the stage for a shift in how we approach treating patients with wet AMD, diabetic retinopathy, macular edema, and other retinal diseases, but many questions remain regarding how their efficacy and safety compare to the reference products and how we can best talk to our patients about these treatment options. To help shed light on these and other FAQs, Dr. Mary Katherine Cheeley speaks with Dr. Arghavan Almony, Adjunct Assistant Professor at Wallace School of Osteopathic Medicine at Campbell University in North Carolina.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Arghavan Almony, MD

The production of biosimilar therapies is setting the stage for a shift in how we approach treating patients with wet AMD, diabetic retinopathy, macular edema, and other retinal diseases, but many questions remain regarding how their efficacy and safety compare to the reference products and how we can best talk to our patients about these treatment options. To help shed light on these and other FAQs, Dr. Mary Katherine Cheeley speaks with Dr. Arghavan Almony, Adjunct Assistant Professor at Wallace School of Osteopathic Medicine at Campbell University in North Carolina.

Host: John Buse, MD, PhD
Guest: Simon Heller, MD

Amid the crisis around the cost of diabetes care worldwide, biosimilar insulins could help save millions of dollars and allow more patients to be treated safely and effectively. But how exactly are these products approved, and how do they compare to the original product? Find out with Dr. John Buse and Dr. Simon Heller, Professor of Clinical Diabetes at the University of Sheffield and the Director of Research and Development at Sheffield Teaching Hospitals Foundation Trust in the United Kingdom. Together, they’ll review Dr. Heller’s recent paper on biosimilar basal insulins that was published in Clinical Diabetes.

Host: John Buse, MD, PhD
Guest: Simon Heller, MD

Amid the crisis around the cost of diabetes care worldwide, biosimilar insulins could help save millions of dollars and allow more patients to be treated safely and effectively. But how exactly are these products approved, and how do they compare to the original product? Find out with Dr. John Buse and Dr. Simon Heller, Professor of Clinical Diabetes at the University of Sheffield and the Director of Research and Development at Sheffield Teaching Hospitals Foundation Trust in the United Kingdom. Together, they’ll review Dr. Heller’s recent paper on biosimilar basal insulins that was published in Clinical Diabetes.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Elizabeth Cook, PharmD, AE-C, BCACP, CDCES

With a shortage of insulin products in the United States, our diabetic patients are left without lifesaving medications, making this a prominent barrier in clinical practice. However, insulin biosimilars may offer more accessibility and affordability, but what do we know about them? Join Dr. Mary Katherine Cheeley as she speaks with Dr. Lizzie Cook, Clinical Pharmacist at Robert J. Dole Veteran Affairs Medical Center in Wichita, Kansas.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Elizabeth Cook, PharmD, AE-C, BCACP, CDCES

With a shortage of insulin products in the United States, our diabetic patients are left without lifesaving medications, making this a prominent barrier in clinical practice. However, insulin biosimilars may offer more accessibility and affordability, but what do we know about them? Join Dr. Mary Katherine Cheeley as she speaks with Dr. Lizzie Cook, Clinical Pharmacist at Robert J. Dole Veteran Affairs Medical Center in Wichita, Kansas.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Shubha Bhat, PharmD

Fortunately, there are a lot of studies that have evaluated biosimilars in inflammatory bowel disease (IBD), and those all confirmed that biosimilars are safe, effective, and do not result in worsening patient outcomes. But are we using biosimilars enough in the treatment of IBD? Dive in with Dr. Mary Katherine Cheeley as she speaks with Dr. Shubha Bhat, Clinical Pharmacist in the Digestive Disease Institute at the Cleveland Clinic.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Shubha Bhat, PharmD

Fortunately, there are a lot of studies that have evaluated biosimilars in inflammatory bowel disease (IBD), and those all confirmed that biosimilars are safe, effective, and do not result in worsening patient outcomes. But are we using biosimilars enough in the treatment of IBD? Dive in with Dr. Mary Katherine Cheeley as she speaks with Dr. Shubha Bhat, Clinical Pharmacist in the Digestive Disease Institute at the Cleveland Clinic.

Host: Raj Chovatiya, MD, PhD
Guest: Steven R. Feldman, MD, PhD

The biologics we know are revolutionary treatments for our patients with psoriasis and now other inflammatory skin diseases. So how do biosimilars play a part in the evolving treatment of psoriasis? Learn more with Dr. Raj Chovatiya as he dives further into biosimilars with Dr. Steve Feldman, Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

Host: Raj Chovatiya, MD, PhD
Guest: Steven R. Feldman, MD, PhD

The biologics we know are revolutionary treatments for our patients with psoriasis and now other inflammatory skin diseases. So how do biosimilars play a part in the evolving treatment of psoriasis? Learn more with Dr. Raj Chovatiya as he dives further into biosimilars with Dr. Steve Feldman, Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

Host: Steven Edelman, MD
Guest: Lutz Heinemann, PhD

Biosimilar insulin is an attractive market to a number of American and European pharmaceutical companies. Biosimilar insulin manufacture is complicated for a number of reasons. Guest host Dr. Timothy Bailey talks with Dr. Lutz Heinemann, director of scientific services at Profil Institute for Clinical Research in San Diego and headquartered in Neuss, Germany, about the challenges and guidelines around producing safe and effective biosimilars. And, for healthcare providers, what are the practical aspects of switching to a biosimilar insulin?

Host: Steven Edelman, MD
Guest: Lutz Heinemann, PhD

Biosimilar insulin is an attractive market to a number of American and European pharmaceutical companies. Biosimilar insulin manufacture is complicated for a number of reasons. Guest host Dr. Timothy Bailey talks with Dr. Lutz Heinemann, director of scientific services at Profil Institute for Clinical Research in San Diego and headquartered in Neuss, Germany, about the challenges and guidelines around producing safe and effective biosimilars. And, for healthcare providers, what are the practical aspects of switching to a biosimilar insulin?

Host: Steven Edelman, MD
Guest: Lutz Heinemann, PhD

Biosimilar insulin is an attractive market to a number of American and European pharmaceutical companies. Biosimilar insulin manufacture is complicated for a number of reasons. Guest host Dr. Timothy Bailey talks with Dr. Lutz Heinemann, director of scientific services at Profil Institute for Clinical Research in San Diego and headquartered in Neuss, Germany, about the challenges and guidelines around producing safe and effective biosimilars. And, for healthcare providers, what are the practical aspects of switching to a biosimilar insulin?

Host: Steven Edelman, MD
Guest: Lutz Heinemann, PhD

Biosimilar insulin is an attractive market to a number of American and European pharmaceutical companies. Biosimilar insulin manufacture is complicated for a number of reasons. Guest host Dr. Timothy Bailey talks with Dr. Lutz Heinemann, director of scientific services at Profil Institute for Clinical Research in San Diego and headquartered in Neuss, Germany, about the challenges and guidelines around producing safe and effective biosimilars. And, for healthcare providers, what are the practical aspects of switching to a biosimilar insulin?

Host: Bruce Japsen
Guest: Tom Dilenge

There appears to be movement in the US to bring less expensive versions of biotech drugs to market. But the brand name drug industry wants these so-called biosimilars to adhere to rigorous safety and efficacy standards currently not built into US laws. Tom DiLenge, vice president and general counsel for the Biotechnology Industry Organization, tells host Bruce Japsen about a palatable pathway biotech companies would like to see approved by Congress to bring cheaper biotech drugs to the US market.

Host: Bruce Japsen
Guest: Tom Dilenge

There appears to be movement in the US to bring less expensive versions of biotech drugs to market. But the brand name drug industry wants these so-called biosimilars to adhere to rigorous safety and efficacy standards currently not built into US laws. Tom DiLenge, vice president and general counsel for the Biotechnology Industry Organization, tells host Bruce Japsen about a palatable pathway biotech companies would like to see approved by Congress to bring cheaper biotech drugs to the US market.

Host: Bruce Japsen
Guest: Tom Dilenge

There appears to be movement in the US to bring less expensive versions of biotech drugs to market. But the brand name drug industry wants these so-called biosimilars to adhere to rigorous safety and efficacy standards currently not built into US laws. Tom DiLenge, vice president and general counsel for the Biotechnology Industry Organization, tells host Bruce Japsen about a palatable pathway biotech companies would like to see approved by Congress to bring cheaper biotech drugs to the US market.